We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
RIM
351
Rainier Investment Management
Washington
$8.66M -$1.31M -20,460 -11%
WSFS
352
Wilmington Savings Fund Society
Delaware
$8.62M -$196K -3,052 -2%
GLRA
353
Gerald L. Ray & Associates
Texas
$8.55M +$1.73M +26,930 +20%
KPF
354
K2 Principal Fund
Ontario, Canada
$8.53M +$10.2M +158,200 New
IRF
355
IBM Retirement Fund
New York
$8.51M -$3.96M -61,669 -28%
HCMNY
356
Howard Capital Management (New York)
New York
$8.47M +$226K +3,518 +2%
SM
357
Sabby Management
Florida
$8.46M +$10.1M +156,887 New
ProShare Advisors
358
ProShare Advisors
Maryland
$8.42M -$4.1M -63,877 -29%
FFSOTS
359
Fiduciary Financial Services of The Southwest
Texas
$8.41M -$479K -7,452 -5%
MFS
360
MSI Financial Services
Massachusetts
$8.39M +$469K +7,305 +5%
DIA
361
Denver Investment Advisors
Colorado
$8.36M +$424K +6,604 +4%
JWBC
362
J.W. Burns & Co
New York
$8.34M -$665K -10,359 -6%
DADC
363
D.A. Davidson & Co
Montana
$8.33M +$2.25M +35,002 +29%
Cohen & Steers
364
Cohen & Steers
New York
$8.29M +$9.87M +153,696 New
CIBC Asset Management
365
CIBC Asset Management
Ontario, Canada
$8.08M -$867K -13,492 -8%
AB
366
Amalgamated Bank
New York
$8.06M +$1.22K +19 +0%
CCM
367
Covington Capital Management
California
$8.04M +$466K +7,260 +5%
UAM
368
UAS Asset Management
New York
$8.04M +$4.95M +77,050 +107%
LIC
369
Lodestar Investment Counsel
Illinois
$8.04M +$7.9M +122,982 +470%
NIA
370
Northstar Investment Advisors
Colorado
$8.03M +$223K +3,468 +2%
SLAM
371
Swiss Life Asset Management
$7.9M
Janus Henderson Group
372
Janus Henderson Group
United Kingdom
$7.81M -$3.56M -55,431 -28%
TBA
373
Tower Bridge Advisors
Pennsylvania
$7.79M +$1.17M +18,150 +14%
CAI
374
Capital Advisors Inc
Oklahoma
$7.68M +$1.97M +30,693 +27%
JPMIA
375
J.P. Marvel Investment Advisors
Massachusetts
$7.63M -$3.63M -56,560 -29%

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.